No Data
Zhe Jiang Dayang Biotech Group's (SZSE:003017) Soft Earnings Are Actually Better Than They Appear
Ocean Bio: Report for the third quarter of 2024
zhejiang dayang biotech group (003017.SZ): plans to invest 0.302 billion yuan to build a project for the relocation and expansion of 800 tons/year of ammeline hydrochloride.
Zhejiang Dayang Biotech Group (003017.SZ) announced on October 18 that the company held its 5th board of directors' 20th meeting on October 17, 2024, and approved the proposal on investing in the construction of a technological transformation project to relocate and expand the production capacity of 800 tons of amine propylamine hydrochloride annually. The company agreed to invest 0.3019 billion RMB of self-raised funds to carry out this project. In order to further expand the scale of the company's advantageous product operation, enhance product market competitiveness, and also respond to Jiande's "exit two, enter three" and industrial transformation policies, it will involve existing hazardous chemicals.
zhejiang dayang biotech group (003017.SZ) plans to invest 0.302 billion yuan to build a project for relocating and expanding the annual production of 800 tons of amine propanol chloride.
Zhìtōng Cái Jīn APP message, zhejiang dayang biotech group (003017.SZ) announced that the company plans to use self-raised funds of 0.302 billion yuan (currency under...
Zhejiang Dayang Biotech Group (003017.SZ): Net income in the third quarter was 19.8295 million yuan, a year-on-year increase of 21.51%.
On October 18, GeLongHui reported that Zhejiang Dayang Biotech Group (003017.SZ) released its third quarter report for 2024. In the third quarter of 2024, the company achieved revenue of 0.235 billion yuan, a 0.64% increase from the same period last year; the net income attributable to shareholders of the listed company was 19.8295 million yuan, a 21.51% increase from the same period last year; the net income profit after deducting non-recurring gains and losses was 19.097 million yuan, a 49.81% increase from the same period last year; the basic earnings per share was 0.23 yuan/share.
Zhejiang Dayang Biotech Group (003017.SZ): The employee stock ownership plan for 2024 has been completed without any trade transfers.
On September 10, GeLongHui reported that on September 10, 2024, Zhejiang Dayang Biotech Group (003017.SZ) announced that the company had received a "Securities Transfer Registration Confirmation" issued by the Shenzhen Branch of China Securities Depository and Clearing Corporation Limited, stating that 1,947,030 shares of the company's stocks held by the "Special Securities Account for Repurchase of Zhejiang Dayang Biotech Group Co., Ltd." had been transferred off-market to the "Zhejiang Dayang Biotech Group Co., Ltd.-2024 Employee Stock Ownership Plan" account on September 9, 2024. The transferred shares account for 2.32% of the total share capital of the company. This employee stock ownership plan was implemented through a non-h